Open Orphan’s hVIVO opens a new quarantine clinic in East London

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services contract research organization (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, part of Open Orphan plc, has opened a new quarantine clinic in East London. The new site is based in Whitechapel, directly opposite the Queen Mary BioEnterprise Innovation Centre which houses hVIVO’s 24 bedroom unique state-of-the-art FluCamp site and the recently opened new street-level volunteer screening centre.  The Whitechapel Clinic will act as an extension of hVIVO`s current QMB site. 

The converted 26-bedroom former boutique hotel, which will be known as the Whitechapel Clinic, has the capacity for up to 19 quarantine rooms and will be used as an additional unit for human challenge trials and volunteer recruitment screening. The quarantine rooms are located across three floors of the former hotel, with each level fully converted  to include a nurses station on each floor.

The new site, like QMB, will follow the highest safety standards to deliver each clinical study and volunteer screening visit. Of the 19 rooms, 8 rooms on a single floor are flexible use clinic rooms, meaning they can be used as either quarantine bedrooms for challenge studies or for volunteer screening visits. Each room at the facility has been fully repurposed to the highest standard, with all volunteer rooms equipped with an en-suite bathroom, TV, wardrobe, and tea & coffee making facilities. This will provide a comfortable space for volunteers during studies. The Whitechapel Clinic, like QMB, is also equipped with a 24-hour security presence and a working hour reception desk.

Cathal Friel, Exexcutive Chairman of Open Orphan plc commented: “Our newest quarantine unit greatly increases our capacity to facilitate hVIVO’s pipeline of upcoming studies. Our QMB clinic is now close to full capacity until December 2021, and as such, the newly renovated, state of the art Whitechapel Clinic will allow us to increase our study capacity substantially in the year ahead.

“We have leased the entire former Whitechapel Hotel and managed to convert the space on a very cost efficient basis which is now almost fully booked to capacity for H1 2021. This new facility will be run at the same high standard as our QMB site, and volunteers will be expertly supervised by our highly trained nurses and doctors in a safe and controlled clinical environment.”

Interested in becoming a volunteer?

If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at www.UKCovidChallenge.com.

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com. By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

CMC regulatory team capabilities

For 20+ years, members of the CMC regulatory team supported several (bio)pharmaceutical companies to ensure manufacture of safe, effective, and high-quality drug products for patients globally. The support includes: Independent, trusted advice on your regulatory activities

Open Orphan Plc

How to build up your child’s immune system

Our Top 7 Tips to Boots Your Child’s Immune System Protecting your children from germs, bacteria and illnesses is a common concern for parents. Flu, colds, viruses and infections can cause misery for both you and

Open Orphan Plc

Open Orphan’s hVIVO presenting at the World Vaccine Congress

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, a

Open Orphan Plc

Hay fever season is back with a vengeance

Hay Fever is back! As the most common form of non-infectious rhinitis, hay fever affects 10-30% of adults and up to 40% of children. Hay fever season typically starts in mid-March as trees bloom until May.

Open Orphan Plc

Open Orphan Investor Presentation March 2022 (Video)

Open Orphan plc (LON:ORPH) CEO Yamin ‘Mo’ Khan talks through its March 2022 Investor Presentation. Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and

Open Orphan Plc

Strategies for Non-clinical safety assessment of vaccines

Setting the scene Over the past century, vaccines have made a large impact on public health, as recently demonstrated by the treatment of the worldwide Covid-pandemic. Since, in general, vaccines are administered to healthy individuals, including

Open Orphan Plc

Open Orphan’s hVIVO signs €6m contract for respiratory study

Dublin-listed clinical trials group Open Orphan has announced that its subsidiary Hvivo has signed a £5 million (€6m) human challenge study contract with a European biotechnology company. The study will test the company’s intravenous antiviral candidate for respiratory syncytial virus,

Open Orphan Plc

Open Orphan opens two new testing facilities

Specialist pharmaceutical services clinical research company Open Orphan is opening a new primary FluCamp volunteer recruitment screening facility in London and a secondary FluCamp recruitment facility in Manchester. Open Orphan tests vaccines and antivirals using human

Open Orphan Plc

FluCamps’ UK Covid Challenge summary

FluCamps’ parent company hVIVO recently published results for the world’s first COVID-19 human challenge trial, World’s first COVID-19 Characterisation Study (investis.com), which ran in Spring of 2021. FluCamp recruited 36 volunteers for this trial under the title

Open Orphan Plc

Clinical PK and PD Service at Venn Breda

For more than 20 years, the clinical pharmacokinetic (PK: understanding the kinetics of a drug in terms of absorption, distribution, metabolism and elimination [ADME]) and pharmacodynamic (PD: the biochemical and physiological effects of a drug) team

Open Orphan Plc

Open Orphan names Khan as new CEO

Specialist pharmaceutical services clinical research company Open Orphan has appointed Yamin ‘Mo’ Khan as its chief executive with immediate effect. Mr Khan joined the company’s board as a non-executive director in October 2021 and has worked